Search

Home
Staff
Sarah Al Ashmori Theophile Bigirumurame Andy Bryant Thomas Chadwick Svetlana Cherlin Mike Cole Holly Fisher Tony Fouweather Shaun Hiu Dorcas Kareithi Ann Breeze Konkoth Nan Lin Jingky Lozano-Kuehne Helen Mossop Ellen Moss Jérémie Nsengimana Vicky Ryan Marzieh Shahmandi Moha Shojaei Dawn Teare James Wason Faye Williamson Nina Wilson Sylvia Zhang
PhD students
Ruqayya Azher Nicole Cizauskas Laura Etfer Niamh Fitzgerald Raiann Hamshaw Aritra Mukherjee Pela Okorie Samuel Sarkodie Lou Whitehead
Methodology research
Overview Adaptive designs Master protocols Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures Leveraging External Information Precision Medicine Clinical Trials
Contact

Rohini Sharma

[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation
[$łess$sup$greater$18$łess$/sup$greater$F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.

Published with Wowchemy — the free, open source website builder that empowers creators.